Table 4.
Multiple logistic regression model to identify independent predictors of risk of MRONJ in cancer patients.
| Covariate | OR (CI 95%) | p-Value |
|---|---|---|
| Age | 0.97 (0.93–1.02) | 0.234 |
| Sex (male) | 2.05 (0.50–8.42) | 0.320 |
| Cancer type (ref = lung cancer) | ||
| Breast cancer | 17.56 (1.43–215.05) | 0.025 |
| Multiple myeloma | 16.28(1.49–181.98) | 0.022 |
| Prostate cancer | 17.99 (1.60–204.68) | 0.019 |
| Number of administered doses of zoledronic acid/denosumab | 1.03 (1.01–1.06) | 0.032 |
| Chemotherapy | 1.06 (0.20–5.54) | 0.944 |
| Hormonal therapy | 1.35 (0.22–8.18) | 0.740 |
| Novel molecules | 34.74 (1.39–868.11) | 0.030 |
| Chemotherapy–hormonal therapy | 0.24 (0.03–1.71) | 0.156 |
| Chemotherapy–novel molecules | 0.03 (0.01–1.08) | 0.055 |
| Hormonal therapy–novel molecules | 0.64 (0.09–4.65) | 0.662 |
Legend: OR = Odds Ratio; CI = Confidence Interval. Statistically significant p-values are reported in bold.